[1] Akhtar ST, Umar M, Khaar H, Aslam F, Nisar G, Naseer A, Ahmad S, Osama M. 2016. Sofosbuvir forthe treatment of hepatitis C genotype 3 infected patients in Pakistan. JAMC 28(4Supp l1):S884_S889.
[2] Aziz H, Raza A, Waheed Y, Gill U, Gil ML. 2012. Analysis of variables and interactions
among variables associated with a sustained virological response to pegylated interferonalpha 2a plus ribavirin in hepatitis C virus genotype 3 infected patients. Inter- national Journal of Infectious Diseases 16(8):e597_602 (DOI 10.1016/j.ijid.2012.03.012).
[3] Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L. 2017. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. PLOS ONE 12(7):e0179764 (DOI 10.1371/journal.pone.0179764).
[4] Hill A, Simmons B, Gotham D, Fortunak J. 2016. Rapid reduction in prices for generic Sofosbuvir and Daclatasvir to treat hepatitis C. Journal of Virus Eradication 2(1):28_31.
[5] Ilyas F. 2016. Pakistan ranked 149th in UN health goals. Dawn. 23 September, 2016.
Available at https://www.dawn.com/news/1285528.
[6] Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A. 2017. Treatment of Real-World HCV
genotype 2 infected Japanese patients with Sofosbuvir plus Ribavirin. Biology 6(2):Article 30.
[7] Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. 2015. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77_87 (DOI 10.1002/hep.27259).
[8] Naghavi M, Wang H, Lozano R, Davis A, Liang X. 2015. Global, regional and national age sex specific all cause and cause specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of diseases study 2013. Lancet 385(9963):117_171 (DOI 10.1016/S0140-6736(14)61682-2).
[9] Omata M, Kanda T, Wei L, Ming-Lung Y, Chuang WL. 2016. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatology International 10(5):702_726 (DOI 10.1007/s12072-016-9717-6).
[10] Saeed U, Waheed Y, Ashraf M, Waheed U, Anjum S, Afzal MS. 2015. Estimation of hepatitis B virus, hepatitis C virus, and different clinical parameters in the thalaseemic population of capital twin cities of Pakistan. Virology: Research and Treatment 6:Article 11.
[11] Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014.
Expandedclassification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59(1):318_327 (DOI 10.1002/hep.26744).
[12] Waheed Y, Najmi MH, Aziz H, Waheed H, Imran M, Safi SZ. 2017. Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan.Biomedical
Reports 7(3):263_266 (DOI 10.3892/br.2017.959).
[13] Waheed Y. 2015a. Effect of Interferon plus ribavirin therapy on hepatitis c virus genotype 3 patients from Pakistan: treatment response, side effects and future prospective. Asian Pacific Journal of Tropical Medicine 8(2):85_89 (DOI 10.1016/S1995-7645(14)60193-0).
[14] Waheed Y. 2015b. Transition from millennium development goals to sustainable development goals and hepatitis. Pathogens and Global Health 109(8):353 (DOI 10.1080/20477724.2015.1126035).
[15] Waheed Y, Shafi T, Safi SZ, Qadri I. 2009. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World Journal of Gastroenterology 15(45):5647_5653 (DOI 10.3748/wjg.15.5647).
[16] World Health Organization. 2017. Global hepatitis report 2017. Available at http:// apps. who.int/ iris/ bitstream/ handle/ 10665/ 255016/ 9789241565455-eng.pdf;jsessionid= E2D0796013167FC7FFA0295C58EF490D?sequence=1.
[17] World Health Organization. 2016. Global health sector strategies on viral hepatitis 2016_2021. Available at http:// apps.who.int/ gb/ ebwha/ pdf_files/WHA69/A69_32- en.pdf?ua=1.
[18] Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R. 2014. Sofosbuvir and Ribavirin in HCV genotype 2 and 3. New England Journal of Medicine 370(21):1993_2001 (DOI 10.1056/NEJMoa1316145).